Katharine Peterson serves as Executive at Acrivon Therapeutics, Inc., where they oversee executive responsibilities. Since joining the company, Katharine Peterson has executed 4 insider transactions totaling $0, demonstrating a balanced approach to their equity position. Their most recent transaction on Nov 14, 2025 involved selling 99 shares valued at $222.
Katharine Peterson currently holds 4,122 shares of Acrivon Therapeutics, Inc. (ACRV), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Katharine Peterson has been a net neutral trader of ACRV stock. They have purchased $0 and sold $0 worth of shares.
Katharine Peterson's most recent insider trade was on Nov 14, 2025, when they sold 99 shares at $2.24 per share.
Get notified when new Form 4 filings are submitted
| $1.39 |
| Discretionary |
| Aug 14, 2024 | ACRV | $695 | Payment | 99 | $7.02 | Discretionary |
| May 14, 2024 | ACRV | $828 | Payment | 99 | $8.36 | Discretionary |